(MENAFN- America News Hour) Research Nester published a report titled
“Pulmonary Drug Delivery Devices Market: Global Demand Analysis & Opportunity Outlook 2035”
which delivers detailed overview of the global pulmonary drug delivery devices market in terms of market segmentation by product, application, distribution channel, and by region.
Further, for the in-depth analysis, the report encompasses the industry growth indicators, restraints, supply and demand risk, along with detailed discussion on current and future market trends that are associated with the growth of the market.
The global pulmonary drug delivery devices market is anticipated to grow with a CAGR of ~7% during the forecast period, i.e., 2023-2035. The market is segmented by
application into asthma, cystic fibrosis, COPD, allergic rhinitis, and others.
Out of these, the
COPD
segment is anticipated to garner the largest revenue by the end of 2033.
Government policies provide subsidies for COPD treatment and non-governmental organizations are increasingly providing COPD treatment and the increasing prevalence of COPD among the population is expected to augment segment growth during the forecast period.
Get a Sample PDF Brochure:
The global pulmonary drug delivery devices market is estimated to garner significant revenue
by the end of 2033, up from a modest revenue
in the year 2023. Rising cases of chronic respiratory diseases, extensive exposure to air pollution, increasing consumption of tobacco smoking along with rising exports of medical and anesthetic appliances
are some of the major factors anticipated to drive the growth of the market during the forecast period.
Geographically, the global pulmonary drug delivery devices
market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Out of these, the market in North America is projected to garner the largest revenue by the end of 2033. The rising incidence of
respiratory diseases such as COPD, chronic bronchitis, and asthma in the region,
a large number of key players and
lifestyle changes
are expected to drive the regional market during the forecast period. For instance, chronic bronchitis affected 8.9 million adults over the age of 18 in the United States in 2018, or 3.5%.
The research is global in nature and covers detailed analysis on the market in North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC [Finland, Sweden, Norway, Denmark], Poland, Turkey, Russia, Rest of Europe), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Asia-Pacific (China, India, Japan, South Korea, Indonesia, Singapore, Malaysia, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa). In addition, analysis comprising market size, Y-O-Y growth & opportunity analysis, market players' competitive study, investment opportunities, demand for future outlook etc. has also been covered and displayed in the research report.
Browse the full report summary:
Occurrence Of Chronic Respiratory Diseases
to Drive the Market Growth
It was observed that chronic respiratory diseases contributed to nearly 250,700 deaths in women and 260,400 deaths in men in the United States.
Asthma and COPD are chronic respiratory diseases commonly treated with pulmonary devices that deliver medication directly to the airways, like inhalers. Both preventive and therapeutic medications are used to treat chronic conditions. Consequently, respiratory diseases are expected to drive the global pulmonary drug delivery devices market growth over the forecast period.
However, variety of drug delivery systems are expected to operate as key restraint to the growth of global pulmonary drug delivery devices market over the forecast period.
This report also provides the existing competitive scenario of some of the key players of the global pulmonary drug delivery devices market which includes company profiling of Novartis AG, Lupin Limited, Briggs Healthcare, Boehringer Ingelheim GmbH, Koninklijke Philips N.V., Merck & Co., Inc, 3M Healthcare, AstraZeneca plc, GlaxoSmithKline plc and GF Health Products, Inc. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global pulmonary drug delivery devices market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.
Contact The Industry Experts / Analysts For A Consultation Call @
Research Nester is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision in order to avoid future uncertainties.
Contact for more Info:
AJ Daniel
Email:
U.S. Phone: +1 646 586 9123
U.K. Phone: +44 203 608 5919